Metformin and Other Sulfonylureas for Glycemic Control in Type 2 Diabetic Patients at a Tertiary Care Hospital in Jammu & Kashmir

BACKGROUND Diabetes mellitus (DM) is a common disease that causes high blood sugar levels and a wide range of symptoms, including polydipsia, polyuria, and changes in weight. The A1C level is very important when it comes to the main treatment for diabetes. It's called the A1C level because it shows the average blood glucose level over the last two to three months. People with diabetes are treated with lifestyle changes and a combination of pharmacological agents to keep their blood sugar levels in check for a long time. The objective of this study was to evaluate the information about Metformin and other Sulfonylureas for Glycemic Control in Type 2 Diabetic Patients at a Tertiary Care Hospital in Jammu & Kashmir. METHODS A 4 month-long observational study was set up with a prospective design and a convenient sampling method. From a diabetes clinic in Jammu and Kashmir, 200 people were chosen to be part of the study. People between the ages of 20 and 60 who had diabetes and were taking Metformin and Sulfonylureas were included in this study. People who had Retinopathy, Nephropathy, and Cognitive impairment were not included. RESULTS In our study, 34 percent of the people who went to the Diabetic Management Center of the hospital were men, and 66 percent were women. Out of 200 patients, 85 percent of them had time to exercise, 56 percent had diabetes because it ran in their families, and 44 percent had diabetes because of metabolic causes. Metformin was given to about 80% of the patients, and sulfonylureas were used by only 20% of the people. In a very bad situation, out of 50 people who took the survey, only 5% used insulin. HbA1C tests were ordered for 90% of the patients in the group of 200. CONCLUSIONS All over the world, people are suffering from type II diabetes. Several other metabolic disorders are linked to type II diabetes. Excessive hepatic glucose generation, peripheral insulin resistance, and impaired beta-cell secretory activity are the primary pathological abnormalities in diabetes. When it comes to glycemic control, Metformin does not raise insulin levels, but it does reduce the amount of glucose absorbed from the intestines. Sulfonylureas reduce hypoglycemia in metabolic disorders.